162 related articles for article (PubMed ID: 26200283)
1. A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
Tamiya A; Shimizu S; Atagi S
J Thorac Oncol; 2015 Aug; 10(8):e74. PubMed ID: 26200283
[No Abstract] [Full Text] [Related]
2. EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib.
Huang T; Engelmann BJ; Morgan RM; Absher KJ; Kolesar JM; Villano JL
Cancer Chemother Pharmacol; 2018 May; 81(5):965-968. PubMed ID: 29610932
[TBL] [Abstract][Full Text] [Related]
3. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
5. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
6. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract][Full Text] [Related]
7. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
9. A selective ALK inhibitor in ALK-rearranged patients.
Yang JC
Lancet Oncol; 2013 Jun; 14(7):564-5. PubMed ID: 23639469
[No Abstract] [Full Text] [Related]
10. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
Kawamura T; Murakami H; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
Invest New Drugs; 2019 Feb; 37(1):184-187. PubMed ID: 29971546
[TBL] [Abstract][Full Text] [Related]
11. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Seto T; Kiura K; Nishio M; Nakagawa K; Maemondo M; Inoue A; Hida T; Yamamoto N; Yoshioka H; Harada M; Ohe Y; Nogami N; Takeuchi K; Shimada T; Tanaka T; Tamura T
Lancet Oncol; 2013 Jun; 14(7):590-8. PubMed ID: 23639470
[TBL] [Abstract][Full Text] [Related]
12. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract][Full Text] [Related]
13. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
15. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
Matsuda H; Hara M; Iwakami SI; Takahashi K
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33906872
[TBL] [Abstract][Full Text] [Related]
16. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Santarpia M; Altavilla G; Rosell R
Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
[TBL] [Abstract][Full Text] [Related]
17. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
Pal SK; Bergerot P; Dizman N; Bergerot C; Adashek J; Madison R; Chung JH; Ali SM; Jones JO; Salgia R
Eur Urol; 2018 Jul; 74(1):124-128. PubMed ID: 29685646
[No Abstract] [Full Text] [Related]
18. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
[TBL] [Abstract][Full Text] [Related]
19. Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
Nakanishi Y; Masuda S; Iida Y; Takahashi N; Hashimoto S
J Thorac Oncol; 2017 Dec; 12(12):e202-e204. PubMed ID: 29169525
[No Abstract] [Full Text] [Related]
20. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
